MOR 106

Drug Profile

MOR 106

Alternative Names: MOR106

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Galapagos NV; MorphoSys
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin-17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Atopic dermatitis

Most Recent Events

  • 01 Aug 2017 Galapagos and MorphoSys completes a phase I trial in Atopic dermatitis in Romania, Moldova, Belgium, Hungary(IV) (NCT02739009)
  • 29 Sep 2016 Phase-I clinical trials in Atopic dermatitis in Hungary (IV) (NCT02739009)
  • 07 Apr 2016 Phase-I clinical trials in Atopic dermatitis in Belgium (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top